Thursday, December 1, 2022
HomeLatest NewsFederal NewsCMS proposes rule to require manufacturers to disclose drug prices

CMS proposes rule to require manufacturers to disclose drug prices

The Centers for Medicare & Medicaid Services (CMS) has proposed a rule (CMS-4187) that will require prescription drug manufacturers to disclose in television ads the wholesale acquisition cost for Medicare or Medicaid prescription drugs.

The proposed rule is the latest in President Trump’s efforts to lower prescription drug prices and increase price transparency. Under the proposed rule, the price required to be posted would be for a typical course of treatment for an acute medication like an antibiotic, or a 30-day supply of medication for a chronic condition that is taken every month. The posting would take the form of a legible statement at the end of the ad. Prescription drugs with a list price of less than $35 per month would be exempt.

Read the policy brief on CMS-4187 and the proposed rule. Comments will be accepted until Dec. 17 and can be submitted here.

Stay Connected

Unified Voice Newsletter

Events This Month

december

01dec11:30 am12:30 pmPalliative Care State of the Field 2022CAPC Webinar

01dec12:30 pm1:30 pmPalliative Care: End of Life Decisions: Ethical and Legal Aspects of Palliative CareProject ECHO

01dec2:00 pm3:30 pmHome Health Regulatory Update for 2023SDAHO Webinar

02decAll Day032nd Annual Walking Forward Health Forum and Policy Symposium

06dec11:00 am12:00 pmEarly Childhood Comprehensive Systems (ECCS) CollaborativeSDAHO Webinar


By submitting this form, you are consenting to receive marketing emails from: SDAHO, 3708 W Brooks Place, Sioux Falls, SD, 57106, http://sdaho.org. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact